Approval · Notice of Compliance 20944 · 2018
ATORVASTATIN: Notice of Compliance 20944
Issued June 5, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20944
- Date
- June 5, 2018
- Company
- Altamed PharmaBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- LIPITOR (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATORVASTATIN | 02476940 | Cancelled Post Market |
| ATORVASTATIN | 02476959 | Cancelled Post Market |
| ATORVASTATIN | 02476967 | Cancelled Post Market |
| ATORVASTATIN | 02476975 | Cancelled Pre Market |
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB
- ATORVASTATIN CALCIUM 80 MG per TAB